Reforms may speed market access, but EFPIA pushes for reimbursement deadlines
This article was originally published in Scrip
Executive Summary
The European Commission's plans to revise the aged Transparency Directive on pricing and reimbursement processes would cut and enforce timelines for decision making, which would see both generics and innovative drugs enter the market more quickly. Both the generics and R&D-based sectors have welcomed the proposals.